In accordance with Section 3 of the Articles of Association of Orion Corporation, 80,802 A shares have been converted into 80,802 B shares. The conversion has been entered into the Trade Register on ...

If you have already voted your shares of Common Stock or directed CHESS Depositary Nominees Pty Ltd (“CDN”) to vote your CHESS Depositary Interests (“CDIs”) by completing the CDI Voting Instruction ...

Idorsia receives approval from Swissmedic for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral ...

The Series E Warrants and the Series F Warrants will have an exercise price of $0.335 per share. The Series E Warrants will be exercisable immediately and will expire five years from the issuance date ...

In response to these concerns, iCare ABA Therapy has deliberately bounded its AI use. The technology is designed to focus AI on back-office functions: staff onboarding, scheduling reliability, ...

The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of ...

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: ...

Partnership with Strata Critical Medical (NASDAQ:SRTA) enables 24/7, device-to-donor support across the U.S.

About NEXICART-2 NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational ...

Company Webcast The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at ...

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, ...

Dr. Hing C. Wong, the Company’s Founder and CEO, stated, “As a shareholder of Wugen, we are excited to see a high-quality syndicate of institutional investors support Wugen’s continued development of ...